Skip to main content
. 2022 Oct 21;25(Suppl 6):e26009. doi: 10.1002/jia2.26009
Abstract P152 – Table 1. Incidence of metabolic events during follow‐up.
TDF (n = 1446) TAF (n = 1446) OR (95% CI) p
Diabetes, n (%) 20 (1.4) 20 (1.4) 1.00 (0.53 to 1.86) 1.000
Hypertension, n (%) 69 (4.8) 51 (3.5) 0.78 (0.54 to 1.13) 0.193
Use of lipid‐lowering therapy, n (%) 63 (4.4) 61 (4.2) 0.97 (0.67 to 1.38) 0.854
NAFLD, n (%) 84 (5.8) 76 (5.2) 0.90 (0.65 to 1.24) 0.515

NAFLD, non‐alcoholic fatty liver disease.